Elsevier

Sleep Medicine

Volume 23, July 2016, Pages 119-120
Sleep Medicine

Letter to the Editor
I petitioned the FDA to restrict hypnotics: here is why

https://doi.org/10.1016/j.sleep.2015.12.011Get rights and content

Section snippets

Conflict of interest

The ICMJE Uniform Disclosure Form for Potential Conflicts of Interest associated with this article can be viewed by clicking on the following link: http://dx.doi.org/10.1016/j.sleep.2015.12.011.

. ICMJE Form for Disclosure of Potential Conflicts of Interest form.

References (12)

  • D.F. Kripke et al.

    Hypnotics' association with mortality or cancer: a matched cohort study

    BMJ Open

    (2012)
  • S. Weich et al.

    Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study

    BMJ

    (2014)
  • R.H. Farkas et al.

    Zolpidem and driving impairment – identifying persons at risk

    N Engl J Med

    (2013)
  • D.F. Kripke

    Mortality risk of hypnotics: strengths and limits of evidence

    Drug Saf

    (2015)
  • W.S. Chung et al.

    Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study

    Medicine (Baltimore)

    (2015)
  • A. Case et al.

    Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century

    PNAS

    (2015)
There are more references available in the full text version of this article.

Cited by (0)

View full text